Navigation Links
BioMarin to Host Fourth Quarter and Full Year 2010 Financial Results
Date:1/24/2011

NOVATO, Calif., Jan. 24, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, February 17, at 5:00 p.m. ET to discuss fourth quarter and full year 2010 financial results.U.S. / Canada Dial-in Number:  866.203.3206International Dial-in Number:  617.213.8848Participant Code: 90635895Replay Dial-in Number: 888.286.8010Replay International Dial-in Number: 617.801.6888Replay Code: 22192303Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com.  A replay of the call will be archived on the site for one week following the call.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Other product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN 701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase 1/2 clinical development for the treatment of Pompe disease, and BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase 1/2 clinical development for the treatment of genetically-defined cancers. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin®, Naglazyme® and Kuvan® are registered trademarks of BioMarin Pharmaceutical Inc.

Firdapse™ is a trademark of BioMarin Huxley Ltd.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.

Contacts:Investors

MediaEugenia Shen

Bob PurcellBioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.(415) 506-6570

(415) 506-3267
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease
2. BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers
3. BioMarin to Present at the J.P. Morgan 29th Annual Healthcare Conference
4. BioMarin to Present at the Deutsche Bank 2010 BioFEST Conference
5. BioMarin Completes Partial Exchange of Convertible Notes Due 2013 for Common Stock
6. BioMarin Announces Third Quarter 2010 Financial Results
7. BioMarin to Host a Research and Development Day on October 19th
8. BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors
9. BioMarin to Present at the UBS Global Life Sciences Conference
10. BioMarin to Present at the Stifel Nicolaus Healthcare Conference
11. BioMarin Receives Orphan Drug Designation from the FDA for BMN-701 for the Treatment of Pompe Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... NEW YORK , Feb. 22, 2017 This ... US$ Thousand. The report provides separate comprehensive analytics for the ... , Europe , Asia-Pacific ... World. Annual estimates and forecasts are provided for the period ... for these markets. Market data and analytics are derived from ...
(Date:2/23/2017)... England and DEERFIELD, Ill. ... U.S.A. , Inc., a wholly-owned subsidiary of ... a joint venture between Cambridge Cognition Holdings PLC and ... use of a specially designed app on an Apple ... patients with Major Depressive Disorder (MDD). Depression ...
(Date:2/23/2017)... , Feb. 23, 2017  CTI BioPharma Corp. ... management plans to report its fourth quarter and full ... the close of the U.S. financial markets. Following the ... webcast conference call to discuss the results and provide ... Access to the event can be obtained as follows: ...
Breaking Medicine Technology:
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... Top cosmetic ... Smiling Patriot program today with a new Indiegogo campaign . Individuals are ... homeless veterans in the Los Angeles area, either as a participating patient or through ...
(Date:2/22/2017)... ... February 22, 2017 , ... When it came time ... center in Georgia, PENETRON Specialty Products (PSP) provided the solution. January’s grand opening ... invested $51 million to purchase and renovate the 185,000 square-foot office complex, which ...
(Date:2/22/2017)... Rockville, MD (PRWEB) , ... February 22, 2017 ... ... Direct secure messaging services to the largest network of hospitals, health ... of the National Coordinator for Health Information Technology (ONC-HIT) 2015 Edition Health IT ...
(Date:2/22/2017)... ... February 22, 2017 , ... In a 2012 ... doses or not filling a prescription because they could not afford to pay ... getting medications were 30-60%*. At the same time, hospitals, pharmacies, manufacturers ...
(Date:2/22/2017)... Singapore, Singapore (PRWEB) , ... February 22, 2017 , ... ... high-end medical leads utilizing a simple online checklist. Over a period of just 24 ... with the assistance of an online checklist called T.A.D. , “The internet is not ...
Breaking Medicine News(10 mins):